Lung Cancer Trial Results
Palliative Care Improves Survival, Quality of Life in Advanced Lung Cancer
(Posted: 09/23/2010) - Patients with advanced lung cancer who received early palliative care experienced longer median survival than those who only received palliative care near death, according to results of a randomized clinical trial published August 19, 2010, in the New England Journal of Medicine.
Gefitinib Improves Progression-free Survival for Metastatic Lung Cancers with EGFR Mutations
(Posted: 08/12/2010) - Patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC) who received gefitinib (Iressa) had significantly higher response rates and longer progression-free survival compared with patients who received carboplatin plus paclitaxel, according to results of a phase III trial conducted in Japan.
Long-term Follow-up Provides New Insights on Adjuvant Therapy for Lung Cancer
(Posted: 12/16/2009) - Longer-term follow-up reports from two large, randomized clinical trials of chemotherapy delivered after surgery in patients with non-small cell lung cancer (NSCLC) have yielded disparate results on the value of such treatment.
No Survival Benefit from Adjuvant Chemo in Stage 1B NSCLC
(Posted: 10/30/2008) - The paclitaxel-plus-carboplatin adjuvant chemotherapy regimen offers no survival benefit to patients with stage 1B non-small-cell lung cancer, according to a report published online September 22, 2008, in the Journal of Clinical Oncology.
Radiotherapy Can Prevent Spread of Small-Cell Lung Cancer to the Brain
(Posted: 06/20/2007, Updated: 01/01/2008) - Radiation therapy to the head, given to patients who had responded to chemotherapy for advanced small-cell lung cancer, reduced by about two-thirds the risk that patients' tumors would spread to the brain, according to findings presented at the 2007 ASCO meeting in Chicago.
(Posted: 09/23/2010) - Patients with advanced lung cancer who received early palliative care experienced longer median survival than those who only received palliative care near death, according to results of a randomized clinical trial published August 19, 2010, in the New England Journal of Medicine.
Gefitinib Improves Progression-free Survival for Metastatic Lung Cancers with EGFR Mutations
(Posted: 08/12/2010) - Patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC) who received gefitinib (Iressa) had significantly higher response rates and longer progression-free survival compared with patients who received carboplatin plus paclitaxel, according to results of a phase III trial conducted in Japan.
Long-term Follow-up Provides New Insights on Adjuvant Therapy for Lung Cancer
(Posted: 12/16/2009) - Longer-term follow-up reports from two large, randomized clinical trials of chemotherapy delivered after surgery in patients with non-small cell lung cancer (NSCLC) have yielded disparate results on the value of such treatment.
No Survival Benefit from Adjuvant Chemo in Stage 1B NSCLC
(Posted: 10/30/2008) - The paclitaxel-plus-carboplatin adjuvant chemotherapy regimen offers no survival benefit to patients with stage 1B non-small-cell lung cancer, according to a report published online September 22, 2008, in the Journal of Clinical Oncology.
Radiotherapy Can Prevent Spread of Small-Cell Lung Cancer to the Brain
(Posted: 06/20/2007, Updated: 01/01/2008) - Radiation therapy to the head, given to patients who had responded to chemotherapy for advanced small-cell lung cancer, reduced by about two-thirds the risk that patients' tumors would spread to the brain, according to findings presented at the 2007 ASCO meeting in Chicago.
